About alphamab oncology - ALMOF
Alphamab Oncology is an investment holding company. It engages in the research and development, manufacturing and commercialization of biologics of oncology through its subsidiaries. The company was founded by Xu Ting in Novemeber 2008 and is headquartered in Suzhou, China.
ALMOF At a Glance
Alphamab Oncology
175 Fangzhou Road
Suzhou, Jiangsu 215127
| Phone | 86-512-62850800 | Revenue | 78.77M | |
| Industry | Biotechnology | Net Income | -15,850,291.89 | |
| Sector | Health Technology | Employees | 498 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
ALMOF Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 15.367 |
| Price to Book Ratio | 4.952 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -83.953 |
| Enterprise Value to Sales | 13.138 |
| Total Debt to Enterprise Value | 0.017 |
ALMOF Efficiency
| Revenue/Employee | 158,172.955 |
| Income Per Employee | -31,827.895 |
| Receivables Turnover | 6.122 |
| Total Asset Turnover | 0.259 |
ALMOF Liquidity
| Current Ratio | 5.675 |
| Quick Ratio | 5.291 |
| Cash Ratio | 4.808 |
ALMOF Profitability
| Gross Margin | 77.354 |
| Operating Margin | -27.072 |
| Pretax Margin | -20.122 |
| Net Margin | -20.122 |
| Return on Assets | -5.221 |
| Return on Equity | -6.394 |
| Return on Total Capital | -6.04 |
| Return on Invested Capital | -6.024 |
ALMOF Capital Structure
| Total Debt to Total Equity | 7.188 |
| Total Debt to Total Capital | 6.706 |
| Total Debt to Total Assets | 5.864 |
| Long-Term Debt to Equity | 5.104 |
| Long-Term Debt to Total Capital | 4.761 |